Biomarkers are increasingly being included in early-phase clinical trials.41 A good biomarker must predict target engagement and future efficacy.41 Remnant cholesterol satisfies both criteria as its level is influenced by APOC3 and predicts (and could be causal for) future CAD events. The gene discussed is APOC3; the disease is coronary artery disorder.